In the tumor-agnostic, phase 2 KEYLYNK-007 trial (N=322), durable responses to pembrolizumab plus olaparib were reported among patients with homologous repair (HRR) mutations (e.g., BRCA1/2, PALB2, ATM, RAD51D)34. Here, PALB2 is linked to neoplasm.